NCT05111860View on ClinicalTrials.gov

Neoadjuvant Bevacizumab + Chemotherapy Combined With Short-course Radiotherapy

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

November 1, 2022

Primary Completion Date

August 1, 2024

Study Completion Date

August 1, 2025

Conditions
Neoadjuvant TreatmentRectal CancerBevacizumabRadiotherapy
Interventions
DRUG

Bevacizumab+mFOLFOX6

Bevacizumab 5mg/kg d1 Oxaliplatin 85mg/m2 d1 Calcium Folinate 400mg/m2 d1 5-fluorouridine 400mg/m2 d1 5-fluorouridine 2400mg/m2 46h q2w, 6 cycles

Trial Locations (1)

200020

RECRUITING

Ruijin Hospital, Shanghai

All Listed Sponsors
lead

Shanghai Minimally Invasive Surgery Center

OTHER